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Recently, with the purpose of enhancing the potency of epidermal growth factor receptor (EGFR)-based therapies, we designed a
novel strategy termed ‘Cascade-release targeting’ that seeks to develop molecules capable of degrading to multiple tyrosine kinase
(TK) inhibitors and highly reactive electrophiles, in a stepwise fashion. Here we report on the first prototype of this model, RB24, a
masked methyltriazene, that in addition to being an inhibitor on its own was designed to degrade to RB14, ZR08, RB10þa DNA
alkylating methyldiazonium species. The cascade degradation of RB24 requires the generation of two reactive electrophiles: (a) an
iminium ion and (b) a methyldiazonium ion. Thus, we surmise that these species could alkylate the active site of EGFR, thereby
irreversibly blocking its action and that DNA damage could be induced by the methyldiazonium. Using the EGFR-overexpressing
human epidermoid carcinoma of the vulva cell line, A431, we demonstrate herein that (a) RB24 and its derived species (e.g. RB14,
ZR08) irreversibly inhibit EGFR autophosphorylation, (b) RB24 induced significant levels of DNA strand breaks, (c) sustained
inhibition of EGFR by RB24 was associated with blockade of MAPK activation and c-fos gene expression, (d) RB24 induced
irreversible cell growth inhibition with a 100-fold greater potency than Temodalt, a clinical methyltriazene. The pronounced growth
inhibitory potency of RB24 was attributed to its ability to simultaneously damage DNA and irreversibly block EGFR TK activity.
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Overexpression of the epidermal growth factor receptor (EGFR)
family and its cognate ligand has been correlated with aggressive-
ness and poor prognosis in various tumours such as breast,
ovarian and prostate cancer (Modjtahedi and Dean, 1994; Xie et al,
1995; Turner et al, 1996; Meden and Kuhn, 1997; Chen et al, 2000).
The implication of these receptors in cancer progression has
garnered significant attention and agents capable of blocking
disordered growth signalling mediated by these proteins are now
in a significant number of clinical trials against many cancers. One
such agent, Iressa, a trademark of the AstraZeneca group of
companies, exhibits a broad spectrum of antitumour activity
against many human solid tumour xenografts of various origins
including breast, lung, colorectal and head and neck (Ciardiello
et al, 2001a; Moulder et al, 2001; Heimberger et al, 2002; Magne ´
et al, 2002; Ranson et al, 2002). However, despite the significant
activity of this compound in preclinical models, in Phase II clinical
trial, it only induced a response rate of approximately 10% in a
cohort of patients with non-small-cell lung cancer (NSCLC)
(Magne ´ et al, 2002; Dancey and Freidlin, 2003). Several possible
explanations have been put forth to explain the failure to
demonstrate a benefit: inadequate dosing, reduced drug delivery
to tumour, lack of sustained potency and failure to select patients
on the basis of having tumours in which EGFR presents a growth
advantage (Dancey and Freidlin, 2003).
The lack of sustainability of the antitumour action of reversible
inhibitors has stimulated the design of new irreversible inhibitors
of EGFR tyrosine kinase (TK). One such compound, PD183805,
bearing a 6-acrylamido group designed to alkylate cysteine 773 in
the active site of the ATP-binding pocket irreversibly blocks EGFR
TK and is now in Phase I development in patients with head and
neck, breast and non-small cell lung carcinoma (Ciardiello and
Tortora, 2001b). Other approaches to enhance the potency of
EGFR inhibitor-based therapy include combinations of inhibitors
with several cytotoxic agents including taxol, cytoxan and
adriamycin (Ciardiello et al, 1999, 2001a; Magne ´ et al, 2002;
Dancey and Freidlin, 2003). Within the same line of idea, with the
purpose of developing more potent and targeted therapies, we
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ydeveloped a novel strategy termed ‘Combi-targeting’ that seeks to
synthesise single molecules that are capable of both blocking EGFR
TK and inducing cytotoxicity by damaging DNA (Brahimi et al,
2002; Matheson et al, 2001, 2003a, 2004a; Qiu et al, 2003, 2004;
Rachid et al, 2003). Two such compounds, SMA41 (Matheson et al,
2003a, 2004b) and BJ2000 (Brahimi et al, 2002), the first models
designed to demonstrate the feasibility of this principle, showed
significant DNA-damaging ability and irreversible block of EGFR
autophosphorylation in A431 cells. More importantly, these agents
induced a more sustained antiproliferative activity when compared
with a reversible inhibitor of EGFR (Matheson et al, 2001, 2004b;
Brahimi et al, 2002). In addition, these molecules, also termed
‘Combi-molecules,’ selectively induced antiproliferative activity
against EGFR transfectants in isogenic models (Brahimi et al, 2002;
Matheson et al, 2003a).
In order to further augment the potency of the Combi-targeting
approach, we recently designed RB24 (an acetoxymethyltriazene)
to generate three inhibitors of EGFR and at the final stage of
degradation a methyldiazonium species capable of damaging DNA
(Banerjee et al, 2003). This masked cluster of molecules was
expected to produce more sustained antitumour effects with the
prospect of inducing activities similar or superior to that of
classical combinations involving a reversible EGFR inhibitorþa
cytotoxic drug. Here we study the mechanism of action of RB24,
the first prototype of this strategy termed ‘cascade release’, and
demonstrate the sustainability of its antitumour activity in A431
cells, which overexpress EGFR and its cognate ligand, TGF-a
(Lanzi et al, 1997). The ability of this cell line to aggressively
proliferate by a TGF-a-mediated autocrine induction has made it
an ideal model for studying the mechanism of action of EGFR TK
inhibitors. In addition, these cells express O6-alkylguanine
transferase (O6-AGT), a DNA repair enzyme that by repairing
the O6-alkylguanine DNA adduct confers significant resistance to
AGTþ cells (Lee et al, 1991; Mitchel and Dolan, 1993; Pegg et al,
1995; Cai et al, 2000; Yingna et al, 2000; Matheson et al, 2003b).
MATERIALS AND METHODS
Drug treatment
RB24, RB14, ZR08 and RB10 were reported elsewhere (Banerjee
et al, 2003). Temodalt was provided by Shering-Plough Inc.
(Kenilworth, NJ, USA). In all assays, the drug was dissolved in
DMSO and subsequently diluted in RPMI-1640 containing 10%
fetal bovine serum (FBS) (Wisent Inc., St-Bruno, Canada)
immediately before the treatment of cell cultures. In all assays,
the concentration of DMSO never exceeded 0.2% (v/v).
Cell culture
The cell line used in this study, the human epidermoid carcinoma
of the vulva, A431, was obtained from the American Type Culture
Collection (Manassas, VA, USA). The A431 cell line was
maintained in RPMI-1640 supplemented with 10% FBS and
antibiotics as described previously (Matheson et al, 2001). All
cells were maintained in an atmosphere of 5% CO2.
In vitro cytokinetic growth inhibition assay
To study the irreversible effects of our compounds on cell
proliferation, 200cellswell
 1 were plated in 96-well plates with
serum-containing media. Cells were exposed to each drugþserum
for either 2, 8, 12, 24 or 48h. After each time point, the drug was
removed and cells were washed 2  with PBS and allowed to
recover with fresh serum-containing media for a total of 96h. Cell
growth was measured using the sulphorhodamine B (SRB) assay.
Briefly, following drug treatment and recovery, cells were fixed
using 50ml of cold trichloroacetic acid (50%) for 60min at 41C,
washed five times with tap water and stained for 30min at room
temperature with SRB (0.4%) dissolved in acetic acid (0.5%). The
plates were rinsed five times with 1% acetic acid and allowed to air
dry. The resulting coloured residue was dissolved in 200ml of Tris
base (10mM), and optical density was read for each well at 492nm
using a Bio-Rad microplate reader (model 2550). Each point
represents the average of at least two independent experiments run
in triplicate.
Autophosphorylation assay
A431 cells (1 10
6) were preincubated in a six-well plate with 10%
serum at 371C for 48h and starved overnight for 24h, after which
they were exposed to a dose range of each drug for 2h and
subsequently treated with 50ngml
 1 EGF for 15min at 371C. Cells
were washed with PBS and resuspended in cold lysis buffer (50mM
Tris-HCl pH 7.5, 150mM NaCl, 1% Nonidet P-40, 1mM EDTA,
5m M NaF, 1mM Na3VO4, protease inhibitor tablet (Roche
Biochemicals, Laval, Canada)). The lysates were kept on ice for
30min and collected by centrifugation at 10000rpm for 20min at
41C. The concentrations of protein were determined using the Bio-
Rad protein assay kit (Bio-Rad Laboratories, Hercules, CA, USA).
Equal amounts of protein were added to a 10% SDS–polyacryla-
mide gel electrophoresis (SDS–PAGE) and transferred to a
polyvinylidene difluoride membrane (Millipore, Bedford, MA,
USA). Nonspecific binding on the membrane was minimised with
a blocking buffer containing nonfat dry milk (5%) in PBST.
Thereafter, the membranes were incubated with primary anti-
bodies (either antiphosphotyrosine antibody (Upstate Biotechnol-
ogy, Lake Placid, NY, USA) for the detection of phosphotyrosine,
or anti-EGFR (Neomarkers, Fremont, CA, USA)) for determination
of corresponding receptor levels. Blots were incubated with HRP-
goat anti-mouse antibody (Bio-Rad Laboratories) and the bands
visualised with an enhanced chemiluminescence system (Amer-
sham Pharmacia Biotech, Buckinghamshire, UK). Band intensities
were measured using the SynGene GeneTools software package.
To study the effects of RB24 on the activation of extraceullular
signal-regulated kinases 1,2 (Erk1,2), protein lysates were obtained
as described above and Western blot was performed as previously
reported (Tari and Lopez-Berestein, 2000). The membrane was
incubated with antiphosphorylated Erk1,2 antibodies or antibodies
specific for Erk1,2 (Cell Signaling, Beverly, MA, USA).
Reverse EGFR autophosphorylation
This assay was performed as previously described (Fry et al, 1998).
A431 cells were grown to confluence in six-well plates and then
incubated in serum-free medium for 24h. Duplicate sets of cells
were then treated with 30mM of each compound for 90min. One set
of cells was then stimulated with EGF (50ngml
 1) for 15min and
extracts were made as described under the Western blotting
procedure above. The other set of cells was washed free of the
compound with warm serum-free media and incubated for 2h.
Thereafter, the cells were washed, incubated for another 2h,
washed again and then incubated for a further 4h. This set of cells
was then stimulated with EGF and extracts were prepared as for the
first set.
RT–PCR for c-fos expression
A431 cells were grown to confluence in six-well plates and then
incubated in serum-free medium for 24h. Cells were exposed to
the indicated concentrations of the drug prior to stimulation with
EGF (50ngml
 1) for 30min. Total RNA was isolated using the
High Pure RNA Isolation Kit of Roche Molecular Bochemicals
(Germany), following the manufacturer’s instructions. Quantita-
tive analysis of c-fos mRNA and G3PDH mRNA (2mg of RNA for
each sample) was preformed by Titan One Tube RT–PCR Kit
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instructions and using the following primers: 50ATGATGTTCTC
GGGCTTC30 (sense), 50CTCCTGCCAATGCT CTGC30 (antisense)
for c-fos and 50CCATGGAGAAGGCTGGGG30 (sense), 50CAAA
GTTGTCATGGATGACC30 (antisense) for G3PDH.
Alkaline comet assay for quantitation of DNA damage
The alkaline comet assay was performed as previously described
(Matheson et al, 2001). The cells were exposed to drugs (RB24,
RB14 or RB10) for 30min, harvested with trypsin–EDTA,
subsequently collected by centrifugation and resuspended in
PBS. Cell suspensions were diluted to approximately 10
6 cells
and mixed with agarose (1%) in PBS at 371C in a 1:10 dilution.
The gels were cast on Gelbond strips (Mandel Scientific, Guelph,
Canada) using gel-casting chambers, as previously described
(McNamee et al, 2000), and then immediately placed into a lysis
buffer (2.5 M NaCl, 0.1 M tetrasodium EDTA, 10mM Tris-base, 1%
(w/v) N-lauryl sarcosine, 10% (v/v) DMSO and 1% (v/v) Triton X-
100, pH 10.0). After being kept on ice for 30min, the gels were
gently rinsed with distilled water and immersed in a second lysis
buffer (2.5 M NaCl, 0.1 M tetrasodium EDTA, 10mM Tris-base)
containing 1mgml
 1 proteinase K for 60min at 371C. Thereafter,
they were rinsed with distilled water, incubated in alkaline
electrophoresis buffer for 30min at 371C and electrophoresed at
300mA for 20min. The gels were subsequently rinsed with distilled
water and placed in 1 M ammonium acetate for 30min. Thereafter,
they were soaked in 100% ethanol for 2h, dried overnight and
stained with SYBR Gold (1:10000 dilution of stock supplied from
Molecular Probes, Eugene, OR, USA) for 20min. Comets were
visualised at  330 magnification and DNA damage was quanti-
tated using the Tail Moment parameter (i.e. the distance between
the barycentre of the head and the tail of the comet multiplied by
the percentage of DNA within the tail of the comet). A minimum of
50 cell comets were analysed for each sample, using ALKOMET
version 3.1 image analysis software.
RESULTS
Inhibition of EGFR autophosphorylation
Western blot analysis demonstrated that RB24 blocked EGF-
induced EGFR autophosphorylation in A431 cells in a dose-
dependent manner with an IC50E2mM without affecting the levels
of EGFR (Figure 1). RB24 is a degradable molecule capable of
generating an extremely reactive iminium ion intermediate that
may alkylate the receptor and irreversibly inhibit EGFR activity. To
test this hypothesis, we used the reversibility assay previously
described (Fry et al, 1998; Smaill et al, 2000) according to which
the cells were treated with the drug for 90min and the culture
medium repeatedly removed and replaced three times after
treatment, after which EGFR autophosphorylation was measured.
As expected, RB24 at 30mM completely suppressed EGF-dependent
EGFR autophosphorylation in A431 cells immediately after drug
exposure (Figure 2A). However, at 8h post-treatment following
repeated washouts in drug-free medium, EGFR autophosphoryla-
tion activity was completely inhibited in cells treated with RB24,
indicating that the latter is capable of inducing irreversible
inhibition of EGFR autophosphorylation. Similarly, irreversible
inhibition was observed in cells exposed to the daughter molecules,
RB14 and ZR08, however with a 20% recovery of the total activity
(Figure 2B). In contrast, the naked inhibitor, RB10, was shown to
have completely reversible inhibition of EGFR autophosphoryla-
tion (Figure 2A).
Inhibition of EGFR-mediated signalling
Antiproliferative activity induced by RB24 requires the translation
of inhibition of EGFR autophosphorylation into inhibition of
downstream signalling. To determine whether blockade of EGFR
autophosphorylation translates into inhibition of downstream
signalling, we analysed the effect of the parent compound, RB24,
on EGF-induced phosphorylation of Erk1,2 and c-fos expression in
A431 cells. The results showed that RB24 induced complete
inhibition of Erk1,2 phosphorylation at concentrations as low as
5mM without affecting the levels of Erk1,2 (Figure 3). Similarly,
RT–PCR analysis showed that RB24 induced nearly 100%
inhibition of EGF-mediated c-fos gene expression at low concen-
trations (1mM) (Figure 4), indicating that inhibition of EGFR
phosphorylation by RB24 is accompanied by a significant blockade
of EGFR-dependent downstream signalling.
Quantitation of DNA damage
Using the alkaline comet assay, we demonstrated that like TEM
(Matheson et al, 2001), RB24 and RB14 induced a dose-dependent
DNA damage in A431 cells after a 30min drug exposure (Figure 5).
Interestingly, RB24 and RB14 induced identical levels of DNA
damage, which is in agreement with the fact that the former is a
prodrug of the latter. As expected, the reversible inhibitor, RB10,
did not demonstrate any DNA-damaging activity.
Irreversible growth inhibitory activity
SRB assays demonstrated that RB24 and RB14 retained significant
antiproliferative activity after a short 2h exposure and a 4-day
recovery (Figure 6A and B). In contrast, the free inhibitor, RB10,
lost at least 95% of its activity under the same conditions
(Figure 6D). The monoalkyltriazene, ZR08, showed partially
reversible activity with an 85% retention of activity following 2h
drug exposure (Figure 6C). In contrast to the antiproliferative
effects of RB24, increasing exposure time was associated with a
significant increase in potency for all other molecules of the
degradation cascade (RB14, ZR08, RB10). Despite being a potent
+EGF −EGF
+ EGF
0.1M 1M 5M 10M 100M
Phosphotyrosine 
EGFR 
Figure 1 Selective inhibition of EGFR autophosphorylation in intact cells by RB24. Serum-starved A431 cells were preincubated for 2h with the indicated
concentrations of RB24 prior to stimulation with EGF for 15min. An equal amount of cell lysates was analysed by Western blotting using
antiphosphotyrosine antibodies. Membranes were stripped of antiphosphotyrosine and reprobed with anti-EGFR antibodies as a loading control. Band
intensities were measured using the SynGene GeneTools software package.
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significant activity at any of the exposure times in the A431 cells
(Figure 6E). In summary, the strength of the retention of potency
was in the following order: RB244RB144ZR08bRB10.
DISCUSSION
Mechanisms of EGFR TK inhibition
The design of our combi-molecule, RB24, was based on the
premise that acetoxymethyltriazenes are known to be hydrolysed
to a hydroxymethyltriazene intermediate that rapidly degrades
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     RB10
    RB14    RB24    ZR08
+EGF
A
B
Figure 2 Reverse EGFR autophosphorylation in the presence of RB24, RB14, ZR08 and RB10 in A431 cells. (A) Duplicate sets of cells were treated with
30mM of designated compound to be tested as a reversible EGFR inhibitor for 90min. One set of cells was then stimulated with EGF for 15min, and extracts
were made as described under the Western blotting procedure. The other set of cells was washed free of the compound with serum-free media, incubated
for 2h, and further washed twice and incubated for 4h. This set of cells was then stimulated with EGF, and extracts were made similar to the first set. (B)
Comparison between the inhibition of autophosphorylation activity induced by RB24, RB14, ZR08 and RB10. The film was scanned and band intensities
were quantified using Syngene GeneTools software. Values are percentage of control of phosphotyrosine/EGFR.
Phosphorylated Erk1,2 
Erk1,2 
+ EGF
−EGF +EGF 0.1 M 1 M 5 M 10 M 100 M
Figure 3 Effect of RB24 on Erk1,2 activation in A431 cells. Serum-starved cells were preincubated for 2h with the indicated concentrations of RB24 prior
to stimulation with EGF for 15min. Protein lysates were obtained and Western blot was performed as described by Tari and Lopez-Berestein (2000).
+EGF
c-fos 
G3PDH 
−EGF +EGF (M) 10 5 1 0.1
Figure 4 Effect of RB24 on c-fos gene expression in A431 cells. Serum-
starved cells were preincubated for 2h with the indicated concentrations of
RB24 prior to stimulation with EGF for 30min. Quantitative analysis of c-fos
and G3PDH was preformed by RT–PCR as described in Materials and
methods.
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Cameron et al, 1985; Hemens and Vaughan, 1986). The latter
further heterolyses to an aromatic amineþa DNA-damaging
species. In a recent publication (Banerjee et al, 2003), we
demonstrated that indeed RB24 was capable of generating the
ultimate amino compound RB10, in a symmetrically inversed
relationship. As depicted in Scheme 1, decomposition through the
intermediates, RB14 and ZR08, is the sole mechanism by which
RB24 can be converted to RB10. Thus, the significant EGFR
inhibitory potency of the putative intermediates RB14, ZR08 and
RB10 indicates that RB24 would maintain its TK inhibitory
potency throughout the multistep degradation cascade. More
importantly, RB24 and its two derivatives (RB14, ZR08) induced
irreversible inhibition of EGFR TK when tested alone, a protracted
inhibition that may be rationalised in the light of recent data on
the mechanism of irreversible acrylamide-based inhibitors. It is
now known that 4-anilinoquinazolines bearing a 6-acrylamido
group react with the cysteine 773 of EGFR, thereby irreversibly
blocking the receptor (Fry et al, 1998; Smaill et al, 1999, 2000).
Based on the mechanism of decomposition of RB24 (Banerjee et al,
2003), we did not expect a direct reaction between the cysteine
thiol group and the acetoxy moiety. Perhaps, if the iminium ion is
formed in the active site of EGFR, it may react with the cysteine as
depicted in Scheme 2. Addition of thiol group to the iminium ions
of acetoxymethyltriazene has already been reported by Iley et al
(1991) who developed this type of triazenes as lyase inhibitors.
Moreover, the ultimate triazene metabolite of RB24, ZR08, may
also directly alkylate the cysteine residue. Quinazolinotriazenes of
the same class, BJ2000 and SMA41, have already been demon-
strated to induce irreversible inhibition (Brahimi et al, 2002;
Matheson et al, 2003b, 2004b).
Although it was not the focus of this study to identify the site of
alkylation of the receptor, the irreversible nature of TK inhibition
by RB24 indicates that it may have inflicted covalent damage at a
site of EGFR that is critical for its TK activity. In corroboration,
RB10 that does not possess a reactive triazene tail induced
reversible EGFR TK inhibitory activity.
DNA damage
The iminium ion is a stable cation that may not be reactive enough
to account for the strong DNA-damaging potential of RB24.
Despite the significant body of results that confirm its formation
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Figure 5 Quantitation of DNA damage using the alkaline comet assay.
Tail moment was used as a parameter for the detection of DNA damage in
A431 cells exposed to RB24, RB14 and RB10 for 30min. Each point
represents at least two independent experiments.
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yduring the process of hydrolysis of acetoxymethyltriazenes
(Hemens et al, 1984; Hemens and Vaughan, 1986; Iley, 1987;
Vaughan and Manning, 1988; Merrin and Hooper, 1992), its
implication in the DNA-damaging properties of the latter class of
compounds is yet to be demonstrated. In contrast, it is now
common knowledge that the methyldiazonium is capable of
inducing significantly high levels of DNA alkylation particularly
at N7 and O6 positions of guanine, thereby inducing DNA damage
and lethal mutations in tumour cells (Bodell et al, 1985; Tisdale,
1987; Baer et al, 1993). The promutagenic O6-alkylguanine adduct
is considered to be the primary cytotoxic lesion induced by
triazenes. Cells, like A431, that express high levels of AGT, a DNA
repair enzyme that repairs the O6-alkylguanine adduct, are known
to be resistant to alkyltriazenes. In corroboration, the A431 cells
used in the study were markedly insensitive to Temodalt, a cyclic
triazene known to release the methyldiazonium species upon
hydrolysis (Cameron et al, 1985; Gibson et al, 1986; Baig and
Stevens, 1987).
Irreversible growth inhibition
The ability of RB24 to degrade into several species with significant
EGFR inhibitory activities and to damage DNA may perhaps be
responsible for its sustained potency in A431 cells. More
importantly, while its antiproliferative effect was maintained even
4 days after a 2h drug exposure, under the same conditions, ZR08
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Figure 6 Irreversible growth inhibition for RB24, RB14, ZR08, RB10 and TEM in A431 cells. Cells were exposed to (A) RB24, (B) RB14, (C) ZR08, (D)
RB10 or (E) TEM for 2, 8, 12, 24 or 48h following recovery for a total of 96h. Cell growth was measured using SRB assay. Each point represents at least two
independent experiments run in triplicate.
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yinduced a partially reversible growth inhibitory activity. We have
already reported similar results in A431 cells for analogous
quinazolinotriazenes (e.g. SMA41 and BJ2000). Thus, the marked
irreversibility of the action of RB24 may be partially imputed to
additive antiproliferative contribution of species generated during
the degradation steps that precede the formation of ZR08. This
antiproliferative contribution may result from their ability to block
EGFR-mediated growth signalling, since as previously mentioned
the transient iminium ion species generated during these
degradation steps may not damage DNA. The partially reversible
growth inhibitory potency of ZR08 (third step of the cascade) may
perhaps be due to the dependence of its antiproliferative activity
on the ultimately released reversible inhibitor RB10, the concen-
trations of which might have been drastically depleted by multiple
washouts. This indicates that the ultimate antiproliferative effect of
ZR08 is mediated by a combination of DNA damage inflicted by
the methyldiazonium species and EGFR TK inhibitory activity
induced by RB10.
A synergistic interaction between the strong EGFR TK inhibitory
potency and the marked DNA-damaging potential of RB24 may
also partly account for its remarkable potency against the A431
cells. Indeed, blockade of EGFR in these cells was accompanied by
potent inactivation of Erk1,2 kinase and inhibition of c-fos gene
expression. We now know, based on previous experiments, that
blockade of EGFR-mediated signalling may not affect the levels or
function of the AGT enzymes. However, Yacoub et al (2003)
recently demonstrated that EGF upregulates the DNA repair genes
XRCC1 and ERCC1 in prostate cell lines through Erk1,2 signalling.
Thus, blockade of EGFR-mediated signalling may downregulate
the DNA repair enzymes that are involved in the repair of DNA
strand breaks, thereby exacerbating the cytotoxic effect of the
latter lesions.
In conclusion, we have demonstrated that a molecule engineered
to possess complex EGFR inhibitory properties and capable of
further releasing DNA-damaging species could induce significantly
more sustained antiproliferative activity than a reversible inhibitor
of the same class (e.g. RB10). Moreover, its multiple properties
have conferred antiproliferative activity in a cell line in which a
classical methylating agent of the same class does not show any
detectable activity. Thus this model may well represent a new
strategy to ameliorate the chemotherapy of EGF-dependent
refractory tumours. Further studies are ongoing to demonstrate
the potency of this novel drug in vivo.
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